| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/20/1994 | WO1994001089A1 Liposomes, method of preparing them and their use in the preparation of drugs |
| 01/20/1994 | WO1994001074A1 Composition for dermatologic preparation |
| 01/20/1994 | CA2139440A1 Medicaments for the treatment of visceral pain and migraine |
| 01/19/1994 | EP0578965A1 Compositions and methods for treating gastrointestinal disorders |
| 01/19/1994 | EP0578732A1 Chewable antacid compositions. |
| 01/19/1994 | EP0578723A1 PROCESS FOR PURIFICATION OF HMG-CoA REDUCTASE INHIBITORS |
| 01/19/1994 | EP0578687A1 Use of deprenyl to maintain, prevent loss, or recover nerve cell function |
| 01/19/1994 | EP0504307B1 Method of treating septic shock |
| 01/19/1994 | EP0439453B1 Improved method for treatment of gastrointestinal disorders |
| 01/19/1994 | CN1080853A Compositions of n-(phosphonoacetyl)-l-aspartic acid and methods of their use as broad spectrum antivirals |
| 01/18/1994 | US5279832 Active-substance preparation for oral administration, especially to ruminants |
| 01/12/1994 | EP0577760A1 Sequential dosing of antifungal and antiinflammatory compositions |
| 01/12/1994 | EP0423228B1 Immunoconjugates for cancer diagnosis and therapy |
| 01/12/1994 | EP0382716B1 Use of commercial lecithin as skin penetration enhancer |
| 01/11/1994 | US5278143 Prophylactic and therapeutic methods for treating interleukin-mediated edemas |
| 01/11/1994 | US5277907 Regulation of the immune system |
| 01/06/1994 | WO1994000130A1 Compositions for the treatment of arthritis containing phosphonates and nsaids |
| 01/06/1994 | WO1994000124A1 Glycine receptor antagonists and the use thereof |
| 01/06/1994 | WO1994000113A2 Medicaments containing 5-ht4 receptor antagonists |
| 01/06/1994 | WO1994000095A2 Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity |
| 01/06/1994 | WO1993016701A3 Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers |
| 01/06/1994 | CA2138124A1 Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity |
| 01/05/1994 | EP0577225A1 Diagnosis and treatment of inflammation |
| 01/05/1994 | EP0577215A1 Surface modified anticancer nanoparticles |
| 01/05/1994 | EP0577025A2 Angiotensin-II-receptorantagonist for the treatment and prophylaxis of coronary heart diseases |
| 01/05/1994 | EP0577023A2 Angiotensin-II receptor-antagonists for the treatment of arrhythmices |
| 01/05/1994 | EP0576612A1 Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| 01/05/1994 | EP0576603A1 Pharmaceutical combination for the treatment of prostatic hyperplasia, containing a 5 alpha-reductase inhibitor and an antiandrogen |
| 01/04/1994 | US5276044 Leukotriene receptor antagonist and antihistamine complex pharmaceutical compositions |
| 01/04/1994 | US5275824 Therapeutic compositions with controlled release of medicaments supported on crosslinked polymers and coated with polymer films, and their preparation process |
| 01/02/1994 | CA2099447A1 Angiotensin ii receptor antagonists for the treatment and prophylaxis of coronary heart disease |
| 01/02/1994 | CA2099425A1 Angiotensin ii receptor antagonists for the treatment of disturbances in cardiac rhythm |
| 12/29/1993 | EP0575749A2 Use of potassium-channel activators for the manufacture of a medicament for the treatment of gastrointertinal ulcers |
| 12/29/1993 | EP0575484A1 Method for promoting tissue repair and regeneration |
| 12/29/1993 | EP0575464A1 Modified factor vii |
| 12/29/1993 | EP0575321A1 Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy |
| 12/29/1993 | CN1079967A Method for producing carbohydrates |
| 12/29/1993 | CN1079896A Topical aromatic releasing compositions |
| 12/28/1993 | US5274076 N-alpha-acetyl,N-epsilon(histamine-succinyl-glycl)-L-lysyl-L -tyrosyl-N-epsilon(histamine-succinyl-glycyl)-L-lysylamide |
| 12/28/1993 | US5273984 Salts formed between basic histamine H2 -receptor antagonists and bismuth complexes |
| 12/28/1993 | US5273760 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
| 12/28/1993 | CA1325594C Agents for the prophylaxis and therapy of retroviral infections |
| 12/28/1993 | CA1325591C Method for treating malignancy and autoimmune disorders in humans |
| 12/23/1993 | WO1993025225A1 Liposomal formulations for administering to cancer patients |
| 12/23/1993 | WO1993025199A1 Alpha-2-adrenergic agonists for treating presbyopia |
| 12/23/1993 | DE4219659A1 Bronchial asthma treatment with PAF-antagonist - esp. thieno:triazolo:diazepine deriv., in presence of anticholinergic agent for synergistic effect |
| 12/23/1993 | CA2137285A1 Alpha-2-adrenergic agonists for treating presbyopia |
| 12/22/1993 | EP0574424A1 Novel salts/ion pairs of non-steroidal anti-inflammatory drugs in various dosage forms |
| 12/22/1993 | EP0574391A1 Antibodies against the urokinase receptor and their use |
| 12/22/1993 | CN1079651A Minimizing progestin associated breakthrough bleeding |
| 12/21/1993 | US5272263 DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
| 12/21/1993 | US5272253 Cluster conjugates of drugs with antibodies |
| 12/15/1993 | EP0574255A1 New derivatives of non-steroidal anti-inflammatory, analgesic and/or antipyretic substances, their use and pharmaceutical formulations containing them |
| 12/15/1993 | EP0573565A1 Opiate receptor antagonist modulates hyperkinetic movement disorder |
| 12/15/1993 | EP0377722B1 Method for the treatment and the diagnosis of coronary heart disease |
| 12/15/1993 | CN1079386A Estrogen/progestin/antiprogestin method and kit for oral contraception and regulating menses |
| 12/12/1993 | CA2096266A1 Method for the prophylaxis and/or treatment of ulceractive gastrointestinal conditions using a potassium activator and compositions for same |
| 12/09/1993 | WO1993024660A1 Method for inhibition of viral morphogenesis |
| 12/09/1993 | WO1993024650A1 Therapeutic compositions |
| 12/09/1993 | WO1993024144A1 PREPARATION FOR ACTIVATION OF NATURAL KILLER CELLS (NK-CELLS), SAID PREPARATION CONTAINING INTERFERON-α AND HISTAMINE, SEROTONIN OR SUBSTANCES WITH CORRESPONDING RECEPTOR ACTIVITY |
| 12/09/1993 | WO1993024124A1 Compositions based on histamine h2-receptor antagonists and cationic exchangers complexes |
| 12/09/1993 | WO1993024123A1 Methods for treating viral infections |
| 12/09/1993 | WO1993024117A2 Medicaments for the treatment of anxiety |
| 12/09/1993 | WO1993024116A1 Pharmaceutical compositions comprising 5-ht1 receptor agonists and absorption enhancers |
| 12/09/1993 | WO1993024115A1 Anti-rheumatoid arthritic drugs in the treatment of dementia |
| 12/09/1993 | CA2136845A1 Pharmaceutical compositions comprising 5-ht1 receptor agonists and absorption enhancers |
| 12/09/1993 | CA2136623A1 Compositions based on histamine h-2 receptor antagonists and cationic exchangers complexes |
| 12/08/1993 | EP0573253A2 Topical anti-bacterial composition |
| 12/08/1993 | EP0572560A1 Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
| 12/08/1993 | EP0572505A1 Human platelet-derived growth factor receptors |
| 12/07/1993 | US5268384 Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors |
| 12/02/1993 | CA2358076A1 Topical patch for liposomal drug delivery system |
| 12/01/1993 | EP0571613A1 Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| 12/01/1993 | EP0422154B1 Therapeutic use of 5-ht3 receptor antagonists |
| 11/30/1993 | US5266571 Treatment of hemorrhoids with 5-HT2 antagonists |
| 11/30/1993 | CA2070006A1 Method of decreasing excess mucus production and accumulation on the gill epithelium of aquatic animals |
| 11/30/1993 | CA1324763C Treatment of periodontal disease |
| 11/25/1993 | WO1993023572A1 Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| 11/25/1993 | WO1993023083A1 Anhydrous formulations for administering lipophilic agents |
| 11/25/1993 | WO1993023082A1 Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents |
| 11/25/1993 | WO1993023079A1 Method for nonspecific cellular immune stimulation |
| 11/25/1993 | WO1993023069A1 Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
| 11/25/1993 | WO1993023052A1 Use of guanylate cyclase inhibitors in the treatment of shock |
| 11/25/1993 | WO1993023035A2 Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease |
| 11/25/1993 | WO1993023024A1 Diamines in the treatment of arrhythmia |
| 11/25/1993 | WO1993023020A1 Contraception method using competitive progesterone antagonists and novel compounds useful therein |
| 11/25/1993 | WO1993023014A1 Chemotherapeutic drug combinations |
| 11/25/1993 | CA2136091A1 Chemotherapeutic drug combinations |
| 11/25/1993 | CA2135784A1 Method for nonspecific cellular immune stimulation |
| 11/25/1993 | CA2135612A1 Diamines in the treatment of arrhythmia |
| 11/25/1993 | CA2135598A1 Anhydrous formulations for administering lipophilic agents |
| 11/25/1993 | CA2131101A1 Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents |
| 11/24/1993 | EP0570519A1 Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis |
| 11/24/1993 | EP0420862B1 Pharmaceutical composition containing deoxyribonucleosides for wound healing |
| 11/24/1993 | EP0381763B1 Antibody modified with toxin |
| 11/23/1993 | US5264222 Colloidal bismuth subcitrate, reduced absorption |
| 11/23/1993 | US5264221 Liposomes with maleimide groups bonded to thiol groups in proteins for antitumor agents |
| 11/23/1993 | US5264207 Polymeric microspheres |
| 11/18/1993 | EP0569583A1 Controlled use of polyether-substituted tumor agents in diagnosis and therapy |
| 11/18/1993 | EP0362272B1 Method and compositions for making acsf and acsf antagonists |